As a medical research company, successful trial outcomes are a must but business acumen in understanding the market is no less important either. For clinical stage biotech company Pharmaxis (ASX: PXS), their latest addition to the Board of Directors line-up will offer them the best of both worlds with the appointment of healthcare investment researcher
Read More
Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. The granting of the new patent is the third jurisdiction to do so for Neuren with the same application
Read More